AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amorcyte, Inc.
ClinicalTrials.gov Identifier:
NCT01495364
First received: December 9, 2011
Last updated: December 19, 2013
Last verified: February 2013
  Purpose

This study will assess the safety and efficacy of intracoronary artery administered autologous bone marrow derived stem cells in subjects post ST segment elevation myocardial infarction (STEMI). Efficacy will be assessed by evaluating and comparing the autologous stem cell treatment group to the control group via change in myocardial perfusion (RTSS) measured quantitatively by gated single photon emission computed tomography myocardial perfusion imaging (gated SPECT MPI) among other secondary endpoints measured by cardiac MRI in addition to clinical endpoints.


Condition Intervention Phase
ST Segment Elevation Myocardial Infarction
Biological: AMR-001
Other: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction.

Resource links provided by NLM:


Further study details as provided by Amorcyte, Inc.:

Primary Outcome Measures:
  • To determine safety and the effect of intracoronary infusion of AMR-001 on myocardial perfusion (RTSS), measured by gated SPECT MPI at baseline and six months in subjects post-STEMI [ Time Frame: primary outcome measured at 6 months ] [ Designated as safety issue: Yes ]
    primary endpoint includes safety of bone marrow procurement (measured by adverse events) and AMR-001 cell infusion (including incidence of re-stenosis and stent thrombosis in addition to other adverse events)as well as efficacy measured by quantitative by gated SPECT MPI specifically looking at resting total severity score)


Estimated Enrollment: 160
Study Start Date: December 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AMR-001
active treatment - CD34+ cells
Biological: AMR-001
dosage = 10 or more million CD34+ cells via intracoronary infusion
Placebo Comparator: placebo
matching placebo
Other: placebo
matching placebo

Detailed Description:

Efficacy endpoint is at 6 months. Clinical endpoints and safety will be measured through 36 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18 years or older.
  2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation > 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, CPK MB or both).

    Chest pain syndrome can extend to more than 3 days prior to admission if its course is consistent with transient/intermittent ischemia rather than symptoms that are continuous suggesting ongoing infarction extending beyond 3 days.

  3. Successful stent placement and reperfusion within 3 days of chest pain onset and with TIMI Flow score of 2 or 3 and infarct related artery (IRA) with <20% stenosis after revascularization.
  4. Wall motion abnormality associated with the target lesion
  5. NYHA heart failure class I, II or III.
  6. Study entry LVEF <48% determined by CMR no sooner than 96 hours from stent placement.
  7. Able to provide informed written consent and willing to participate in all required study follow-up assessments.
  8. Subjects must have an INR ≤ 2.0 within 2 days of the bone marrow collection.
  9. Subjects must have a Hgb ≥ 10 grams/dL, WBC ≥ 3500 cells/mm3, a platelet count ≥ 100,000 cells/mm3, serum creatinine ≤ 2.5, and total bilirubin ≤ 2.0 within 7 days of the bone marrow collection or by end of screening phase.
  10. Expected survival of at least one year.
  11. Females of child bearing potential agree to use birth control (barrier method accepted) for one month post bone marrow harvest.

EXCLUSION CRITERIA

  1. Continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
  2. Subjects in cardiogenic shock (systolic pressure < 80mm/Hg, on vasopressors, or intra-aortic counterpulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
  3. Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc).
  4. Subjects receiving warfarin who have an INR >2 or with major bleeding requiring active transfusion support.
  5. Subjects who require continuous anticoagulation during the time when the bone marrow harvest is scheduled, as heparin must be discontinued for 4 hours prior to and 24 hours after bone marrow harvest procedure. (See Appendix VII.)
  6. Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
  7. Subjects with known severe immunodeficiency states (AIDS).
  8. Cirrhosis requiring active medical management.
  9. Malignancy requiring active treatment (except basal cell skin cancer).
  10. Subjects with documented active alcohol and /or other substance abuse.
  11. Females of child bearing potential unless a pregnancy test is negative within 7 days of the mini-bone marrow harvest.
  12. Re-occlusion of the IRA prior to the infusion procedure.
  13. Planned revascularization intervention during the next 6 months (A second PCI can be performed if done prior to qualifying CMR at least 96 hours post primary PCI).
  14. Participation in an ongoing investigational trial.
  15. Active or suspected bacterial infection requiring systemic intravenous antibiotics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01495364

  Show 58 Study Locations
Sponsors and Collaborators
Amorcyte, Inc.
Investigators
Study Director: Tom Moss, MD Amorcyte, Inc.
Principal Investigator: Arshed Quyyumi, MD Emory University
  More Information

No publications provided

Responsible Party: Amorcyte, Inc.
ClinicalTrials.gov Identifier: NCT01495364     History of Changes
Other Study ID Numbers: 002
Study First Received: December 9, 2011
Last Updated: December 19, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Amorcyte, Inc.:
STEMI

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 14, 2014